Last checked at 25 Jun 2014 16:11
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Issue of equity and Directors' shareholdings
25 June 2014, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that two Non-Executive Directors of the Company have taken part of their fees for the half-year ended 31 January 2014 in ordinary shares.
The new ordinary shares were issued on 25 June 2014 at a price of 27.5 pence per share, this being the average of the closing mid-market prices for the five business days ending on the day before allotment. The allotment and total holdings following this allotment are shown below.
Director | Shares allotted 25 June 2014 | Ordinary shares held following allotment (% of current issued share capital) | Options over ordinary shares held (% of current issued share capital) |
Oliver James | 9,819 | 136,235 (0.05%) | 118,020 (0.05%) |
Rajesh Chopra | 6,736 | 25,799 (0.01%) | - |
Application has been made to admit the 16,555 new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 1 July 2014. Following admission the number of ordinary shares in issue in the Company will be 264,162,998. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.
Contacts:
e-Therapeutics plc
Steve Medlicott
Tel: +44 (0) 1993 883125
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Fred Walsh / Duncan Monteith
Tel: +44 (0) 20 7886 2500
www.panmure.com